Personalized Oral Ibuprofen Dosing Versus Standard Treatment for Patent Ductus Arteriosus in Preterm Newborns A Pilot Study
Led by Hamilton Health Sciences Corporation · Updated on 2025-08-27
26
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate model-informed precision dosing MIPD of oral ibuprofen compared to standard dosing for treating Patent Ductus Arteriosus PDA in preterm newborns born at or before 27 weeks and 6 days gestational age. PDA is a condition where a passageway between the heart and lungs remains open and can cause serious complications. The study investigates whether adjusting ibuprofen doses based on drug levels in the blood and heart response improves PDA closure rates and safety compared to the usual fixed dosing.
Participants are randomly assigned to one of two groups one receives the standard oral ibuprofen regimen starting with a loading dose followed by two fixed doses at 24-hour intervals, while the other starts with the same loading dose but subsequent doses are adjusted using a Bayesian forecasting model combining blood drug levels and echocardiogram results evaluated every 12 hours. The study uses the Web-Accessible Population Pharmacokinetics Service for PDA WAPPS-PDA to guide personalized dosing in the experimental arm.
During the study, newborns undergo blood sampling at 6, 30, and 54 hours after the initial dose, as well as daily targeted neonatal echocardiograms to assess PDA status. Researchers monitor recruitment feasibility, timeliness of dosing decisions, drug levels, PDA closure rates, need for additional treatments or surgery, and any adverse events over up to 14 days. The study lasts from initial dosing through 96 hours for primary measures and up to 14 days for clinical outcomes, closely tracking drug safety and effectiveness in this vulnerable population.
CONDITIONS
Brief Title
Precision Dosing of Oral Ibuprofen for PDA, A Pilot RCT
Research Team
S
Samira Samiee-Zafarghandy, MD, FRCPC
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Neonates with a gestational age of 27 weeks and 6 days or less
Admitted to the neonatal intensive care unit at McMaster Children's Hospital
Diagnosed with Patent Ductus Arteriosus needing treatment based on targeted neonatal echocardiography
Parent or guardian has provided consent for participation
You will not qualify if you...
Major congenital or genetic abnormalities
Clinical or biochemical liver or kidney failure (AST > 225 U/L, ALT > 150 U/L, or serum creatinine > 130 µmol/L)
Confirmed uncontrolled or active sepsis
Contraindications to oral ibuprofen including severe hyperbilirubinemia needing exchange transfusion
Severe feeding intolerance
Necrotizing enterocolitis
Gastrointestinal perforation
Active bleeding
Severe thrombocytopenia (platelet count < 50×10⁹/L)
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Up to 96 hours after initial dose
Participants receive oral ibuprofen treatment either by standard dosing or by model-informed precision dosing (MIPD) with doses adjusted based on pharmacokinetic and echocardiographic data.
Dosing and assessments occur at initial dose and at 6, 30, 54, and 96 hours post-dose
Follow-up
Duration - Up to 14 days after first dose
Participants are monitored for PDA closure and any treatment-related outcomes or adverse events after treatment completion.
Assessments during routine neonatal care up to 14 days
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Nationwide Study on Small Vulnerable Newborns in China
Observing Preterm, Small for Gestational Age, and Low Birth Weight Infants
Study of Arginine Supplementation Effects on Immune Response in Newborns After Major Bowel Surgery or Necrotising Enterocolitis
The ELEVATE Program for Early Detection and Prediction of Cerebral Palsy
Assessing Motor and Intellectual Outcomes in High-Risk and Healthy Infants
Comparing Cervical Cerclage Plus Vaginal Progesterone to Vaginal Progesterone Alone to Prevent Preterm Birth in Women with Twin Pregnancies and a Short Cervix
Studying Stress and Interaction Between Parents and Preterm Infants Born at 30 to 34 Weeks in the NICU
Umbilical Cord Milking Versus Early Cord Clamping to Reduce Death in Preterm Infants Born Between 30 and 34 Weeks Who Are Non-vigorous at Birth
Early Physiotherapy for At-Risk Infants to Improve Motor Skills and Development
Study of PIMUN Device to Reduce Intermittent Hypoxia and Apnea in Preterm Infants Under 30 Days Old
Study Comparing Nasal Ventilation Methods to Help Preterm Babies With Breathing Problems Using Lung Ultrasound
Proteomic Study of Minor Proteins and Peptides in Human Milk Across Birth Weight Groups and Lactation Stages
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
An optimized ibuprofen dosing scheme for preterm neonates with patent ductus arteriosus, based on a population pharmacokinetic and pharmacodynamic study.
Déborah Hirt, Bart Van Overmeire, Jean-Marc Treluyer...
Association of Placebo, Indomethacin, Ibuprofen, and Acetaminophen With Closure of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Infants: A Systematic Review and Meta-analysis.
Data Analysis Protocol for the Development and Evaluation of Population Pharmacokinetic Models for Incorporation Into the Web-Accessible Population Pharmacokinetic Service - Hemophilia (WAPPS-Hemo).
Alanna McEneny-King, Gary Foster, Alfonso Iorio...